^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 expression + TNFRSF17 expression

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4, TNFRSF17, TNF Receptor Superfamily Member 17, Tumor Necrosis Factor Receptor Superfamily Member 17, B-Cell Maturation Protein, BCMA, Tumor Necrosis Factor Receptor Superfamily, Member 17, B Cell Maturation Antigen, B-Cell Maturation Factor, CD269 Antigen, TNFRSF13A, CD269
    Entrez ID:
    930; 608
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    12ms
    UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (EHA 2023)
    Patients received a median of 2 prior lines (range 2 - 3) of therapy including rituximab and anthracyclines. This first-in-human trial of GC012F,a CD19-BCMA dual targeting CAR-T product, for thetreatment of r/r B-NHL showed a manageablesafety profileand promising clinical responses.The ORR was 100% at month 3 with 77.8% (7/9) achieving CR. GC012F CAR-Tcells were detectablein thetumor biopsies, indicating theinfiltration of CAR-T cells into thetumor lesions.Study with larger cohortand longer follow-up is ongoing. Keywords: CAR-T
    Clinical • P1 data
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD19 expression + TNFRSF17 expression
    |
    Rituxan (rituximab) • GC012F
    1year
    Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma. (ASCO 2023)
    Pts received a median of 2 prior lines (range 2-3) of therapy including rituximab and anthracyclines. This first-in-human trial of GC012F for the treatment of r/r B-NHL showed a manageable safety profile and promising clinical responses. The ORR was 100% at M3 with 77.8% (7/9) achieving CR. GC012F CAR-T cells were detectable in the tumor biopsies, indicating the infiltration of CAR-T cells into the tumor lesions.
    Clinical • P1 data
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD19 expression + TNFRSF17 expression
    |
    Rituxan (rituximab) • GC012F